LUNA INNOVATIONS INCORPORATED — Department of Defense SBIR Phase II: A16-059
LUNA INNOVATIONS INCORPORATED — SBIR Phase II award from Department of Defense.
- Amount
- $991,429
- Agency
- Department of Defense · Army
- Program / Phase
- SBIR · Phase II
- Topic
- A16-059
- Solicitation
- 16.1
- NAICS
- —
- Place of performance
- VA
- Period
- 2017-07-14 → 2020-08-04
Description
Chronic neuropathic pain is a commonly occurring condition and a painful and debilitating problem for millions of Americans. The bulk of these neuropathic pains result from induced peripheral neuropathies, most commonly associated with diabetes, chemotherapy-treated cancers, and extremity injuries. Many drugs that have been shown effective in pain management when taken orally have extremely narrow therapeutic windows to prevent toxicity or undesirable side effects. In order to address the issues with drug-treatment of peripheral neuropathy, Luna Innovations is developing a unique and highly-controllable nanofiber-based transdermal drug delivery system known as TuneCoat-PN for the delivery of liposome-based nerve targeting drugs. The drug delivery nanofiber dressing will be used topically at the site of injury, will be applied by the patient, and will be designed to function with compression garments. The fabrication protocol allows for inclusion of multiple drugs in a single bandage with control over the delivery of each drug.